Nasus Pharma Ltd SEC filings NSRX
Nasus Pharma Ltd has 100 filings in SEC EDGAR's recent list, going back to Aug 30, 2024. Its latest annual report, Form 20-F, was filed on Mar 25, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 8, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Oct 8, 2026 |
| 6-K | Current report (foreign issuer) | Sep 18, 2026 | Sep 18, 2026 |
| 6-K | Current report (foreign issuer) | Sep 14, 2026 | Sep 14, 2026 |
| 6-K | Current report (foreign issuer) | Sep 4, 2026 | Sep 4, 2026 |
| 6-K | Current report (foreign issuer) | Aug 19, 2026 | Aug 19, 2026 |
| 6-K | Current report (foreign issuer) | Aug 17, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jul 28, 2026 | Jul 28, 2026 |
| 6-K | Current report (foreign issuer) | Jun 9, 2026 | Jun 9, 2026 |
| 6-K | Current report (foreign issuer) | Mar 25, 2026 | Mar 25, 2026 |
| 6-K | Current report (foreign issuer) | Mar 16, 2026 | Mar 16, 2026 |
| 6-K | Current report (foreign issuer) | Mar 6, 2026 | Mar 6, 2026 |
| 6-K | Current report (foreign issuer) | Mar 4, 2026 | Mar 4, 2026 |
| 6-K | Current report (foreign issuer) | Feb 24, 2026 | Feb 23, 2026 |
| 6-K | Current report (foreign issuer) | Feb 13, 2026 | Feb 13, 2026 |
| 6-K | Current report (foreign issuer) | Feb 12, 2026 | Feb 11, 2026 |
| 6-K | Current report (foreign issuer) | Jan 29, 2026 | Jan 29, 2026 |
| 6-K | Current report (foreign issuer) | Jan 20, 2026 | Jan 20, 2026 |
| 6-K | Current report (foreign issuer) | Dec 29, 2025 | Jun 30, 2025 |
| 6-K | Current report (foreign issuer) | Dec 22, 2025 | Dec 22, 2025 |
| 6-K | Current report (foreign issuer) | Nov 20, 2025 | Nov 20, 2025 |
| 6-K | Current report (foreign issuer) | Nov 18, 2025 | Nov 18, 2025 |
| 6-K | Current report (foreign issuer) | Nov 3, 2025 | Nov 3, 2025 |
| 6-K | Current report (foreign issuer) | Oct 8, 2025 | Oct 8, 2025 |
| 6-K | Current report (foreign issuer) | Sep 30, 2025 | Sep 30, 2025 |
| 6-K | Current report (foreign issuer) | Sep 5, 2025 | Sep 5, 2025 |
| 6-K | Current report (foreign issuer) | Aug 14, 2025 | Aug 14, 2025 |
Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NSRX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv - Yafo, Israel
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2029039
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.